No Data
No Data
Imunon Announces That An Abstract Highlighting New Overall Survival Data From Phase 2 Ovation 2 Study Of Imnn-001 To Treat Women With Newly Diagnosed Advanced Ovarian Cancer Was Accepted For Oral Presentation at the 2025 American Society of Clinical...
Express News | Imunon Announces Imnn-001 Abstract Accepted for Oral Presentation at 2025 Asco Annual Meeting
IMUNON Announces IMNN-001 Abstract Accepted for Oral Presentation at 2025 ASCO Annual Meeting
Imunon to Offer Up to 10M Shrs and 10M Warrants
Imunon Files to Sell 10M Shares of Common Stock, Warrants
Express News | HC Wainwright & Co. Reiterates Buy on Imunon, Maintains $14 Price Target